Altered patterns of MDM2 and TP53 expression in human bladder cancer

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• TP53 gene (17p13.1) encodes p53, crucial for cell cycle control.
• MDM2 gene (12q13-14) encodes Mdm2 protein.
• TP53 alterations are common in bladder cancer; MDM2 alterations are unstudied in this context.

Purpose of the Study:

• Determine the frequency of MDM2 and TP53 abnormalities in bladder tumors.
• Examine the clinical relevance of altered MDM2 and TP53 expression patterns.

Main Methods:

• Analyzed 87 bladder tumor cases.
• Assessed Mdm2 protein expression via immunohistochemistry (antibody 2A10).
• Studied MDM2 gene amplification by Southern blotting.
• Identified mutant p53 proteins (antibody PAb1801).
• Assessed TP53 intragenic mutations using single-strand conformation polymorphism and sequencing.
• Statistical analysis using Fisher's exact test.

Main Results:

• 26/87 cases showed high Mdm2 protein levels; only 1/87 had MDM2 amplification.
• 36/87 cases displayed p53 nuclear overexpression.
• 16/87 cases had high levels of both Mdm2 and p53 proteins.
• Strong association between Mdm2 and p53 overexpression (P = .018).
• Striking association between Mdm2 overexpression and low-stage, low-grade tumors (P = .0005).

Conclusions:

• Aberrant Mdm2 and p53 phenotypes are frequent in bladder cancer.
• These alterations may be involved in tumorigenesis or progression of urothelial neoplasias.
• This study is the first to report altered MDM2 expression in human bladder tumors, suggesting diagnostic and prognostic value.